文献速递肿瘤 PET/CT核素与放射性配体治疗

一种保留生长抑素受体靶向激动特性的模块化双标记支架

A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.
PubMed 文献 · J Nucl Med · 2017-06-01

本研究以生长抑素受体显像剂DOTATOC为基础,合成多模态螯合(MMC)支架偶联物MMC-TOC,并与常规方法制备的DA-TOC对比,分别偶联IRDye 800并用Cu和64Cu标记。体外实验显示Cu-MMC(IR800)-TOC在环磷酸腺苷抑制和受体内化方面效力更高,体内实验显示64Cu-MMC(IR800)-TOC肿瘤摄取更高且可被奥曲肽阻断。结论提示药物设计影响受体药理学,MMC支架是开发双标记显像剂的有用工具。

要点

  • Cu-MMC(IR800)-TOC抑制环磷酸腺苷的EC50为0.21±0.18 nM,低于Cu-DA(IR800)-TOC的1.38±0.54 nM。
  • 64Cu-MMC(IR800)-TOC肿瘤摄取为5.2±0.2 %ID/g,高于64Cu-DA(IR800)-TOC的3.6±0.4 %ID/g。
  • 奥曲肽阻断使64Cu-MMC(IR800)-TOC肿瘤摄取降低66%,而64Cu-DA(IR800)-TOC摄取未受影响。

核心结论

  • 研究结果表明药物设计影响了受体药理学,并提示MMC支架是开发双标记显像剂的有用工具。

研究设计与样本

  • 在固相上合成MMC偶联物MMC-TOC,并与常规方法制备的类似物DA-TOC对比,两者均通过无铜点击化学偶联IRDye 800。
  • 所得化合物MMC(IR800)-TOC和DA(IR800)-TOC用Cu和64Cu标记,在过表达生长抑素受体亚型2的HEK-293细胞中体外评估激动特性,在AR42J大鼠胰腺癌细胞中测定受体结合特征。
  • 在AR42J异种移植瘤中进行多模态显像。

主要发现

  • Cu-MMC(IR800)-TOC抑制环磷酸腺苷的半数最大有效浓度(EC50)为0.21±0.18 nM,低于Cu-DA(IR800)-TOC的1.38±0.54 nM。
  • Cu-MMC(IR800)-TOC受体内化的EC50为41.9±29.8 nM,低于Cu-DA(IR800)-TOC的455±299 nM。
  • 放射性摄取研究显示奥曲肽阻断引起64Cu-MMC(IR800)-TOC摄取剂量依赖性降低,而64Cu-DA(IR800)-TOC未受影响。
  • 体内研究显示64Cu-MMC(IR800)-TOC肿瘤摄取为5.2±0.2 %ID/g,高于64Cu-DA(IR800)-TOC的3.6±0.4 %ID/g。
  • 奥曲肽体内阻断使64Cu-MMC(IR800)-TOC肿瘤摄取降低66%;64Cu-MMC(IR800)-TOC主要经肝和脾排泄,而64Cu-DA(IR800)-TOC经肾清除。

关键数值与推荐

  • Cu-MMC(IR800)-TOC抑制环磷酸腺苷的EC50为0.21±0.18 nM,Cu-DA(IR800)-TOC为1.38±0.54 nM。
  • Cu-MMC(IR800)-TOC受体内化的EC50为41.9±29.8 nM,Cu-DA(IR800)-TOC为455±299 nM。
  • 64Cu-MMC(IR800)-TOC肿瘤摄取为5.2±0.2 %ID/g,64Cu-DA(IR800)-TOC为3.6±0.4 %ID/g。
  • 奥曲肽阻断使64Cu-MMC(IR800)-TOC肿瘤摄取降低66%。
  • 24小时离体分析显示肿瘤近红外荧光信号,γ计数测得的肿瘤与肌肉比值为5.3±0.8。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fluorescence-guided surgery is an emerging imaging technique that can enhance the ability of surgeons to detect tumors when compared with visual observation. To facilitate characterization, fluorescently labeled probes have been dual-labeled with a radionuclide to enable cross-validation with nuclear imaging. In this study, we selected the somatostatin receptor imaging agent DOTATOC as the foundation for developing a dual-labeled analog. We hypothesized that a customized dual-labeling approach with a multimodality chelation (MMC) scaffold would minimize steric effects of dye conjugation and retain agonist properties. Methods: An MMC conjugate (MMC-TOC) was synthesized on solid-phase and compared with an analog prepared using conventional methods (DA-TOC). Both analogs were conjugated to IRDye 800 using copper-free click chemistry. The resulting compounds, MMC(IR800)-TOC and DA(IR800)-TOC, were labeled with Cu and 64Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 cells to assess agonist properties, and in AR42J rat pancreatic cancer cells to determine receptor binding characteristics. Multimodality imaging was performed in AR42J xenografts. Results: Cu-MMC(IR800)-TOC demonstrated higher potency for cyclic adenosine monophosphate inhibition (half maximal effective concentration [EC50]: 0.21 ± 0.18 vs. 1.38 ± 0.54 nM) and receptor internalization (EC50: 41.9 ± 29.8 vs. 455 ± 299 nM) than Cu-DA(IR800)-TOC. Radioactive uptake studies showed that blocking with octreotide caused a dose-dependent reduction in 64Cu-MMC(IR800)-TOC uptake whereas 64Cu-DA(IR800)-TOC was not affected. In vivo studies revealed higher tumor uptake for 64Cu-MMC(IR800)-TOC than 64Cu-DA(IR800)-TOC (5.2 ± 0.2 vs. 3.6 ± 0.4 percentage injected dose per gram). In vivo blocking studies with octreotide reduced tumor uptake of 64Cu-MMC(IR800)-TOC by 66%. Excretion of 64Cu-MMC(IR800)-TOC was primarily through the liver and spleen whereas 64Cu-DA(IR800)-TOC was cleared through the kidneys. Ex vivo analysis at 24 h confirmed PET/CT data by showing near-infrared fluorescence signal in tumors and a tumor-to-muscle ratio of 5.3 ± 0.8 as determined by γ-counting. Conclusion: The findings demonstrate that drug design affected receptor pharmacology and suggest that the MMC scaffold is a useful tool for the development of dual-labeled imaging agents.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ghosh SC, Rodriguez M, Carmon KS, et al. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. J Nucl Med. 2017. PMID: 28572490. doi:10.2967/jnumed.116.187971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。